Mannose-binding lectin-2 and ficolin-2 gene polymorphisms and clinical risk factors for acute rejection in kidney transplantation

Transplant Immunology

Volumn 30, Issue 2-3, 2014, Pages 71-75

  Wu, Xiaoxia ^a   Wan, Qiquan ^a   Ye, Qifa ^a   Zhou, Jiandang ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Acute rejection; Ficolin 2; Gene polymorphism; Kidney transplantation; Mannose binding lectin; Panel reactive antibodies

Indexed keywords

CYCLOSPORIN; FICOLIN; FICOLIN 2; MANNOSE BINDING LECTIN 2; PANEL REACTIVE ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG; LECTIN; MANNOSE BINDING LECTIN; MBL2 PROTEIN, HUMAN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; FCN2 GENE; FEMALE; GENE SEQUENCE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MBL2 GENE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ACUTE DISEASE; CLINICAL TRIAL; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; GRAFT REJECTION; MIDDLE AGED;

ACUTE DISEASE; ADULT; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LECTINS; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 84896544437     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.10.009     Document Type: Article

References (43)

1. Pratt J.R., Basheer S.A., Sacks S.H. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002, 8:582-587.
2. Petersen S.V., Thiel S., Jensenius J.C. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol Immunol 2001, 38:133-149.
3. Yongqing T., Drentin N., Duncan R.C., et al. Mannose-binding lectin serine proteases and associated proteins of the lectin pathway of complement: two genes, five proteins and many functions?. Biochim Biophys Acta 1853, 2012:253-262.
4. Walport M.J. Complement. First of two parts. N Engl J Med 2001, 344:1058-1066.
5. Walport M.J. Complement. Second of two parts. N Engl J Med 2001, 344:1140-1144.
6. Minchinton R.M., Dean M.M., Clark T.R., et al. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population. Scand J Immunol 2002, 56:630-641.
7. Crosdale D.J., Ollier W.E., Thomson W., et al. Mannose binding lectin (MBL) genotype distributions with relation to serum levels in UK Caucasoids. Eur J Immunogenet 2000, 27:111-117.
8. Turner M.W., Hamvas R.M. Mannose-binding lectin: structure, function, genetics and disease associations. Rev Immunogenet 2000, 2:305-322.
9. Hummelshoj T., Munthe-Fog L., Madsen H.O., et al. Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2. Hum Mol Genet 2005, 14:1651-1658.
10. Bouwman L.H., Roep B.O., Roos A. Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol 2006, 67:247-256.
11. Fildes J.E., Shaw S.M., Walker A.H., et al. Mannose-binding lectin deficiency offers protection from acute graft rejection after heart transplantation. J Heart Lung Transplant 2008, 27:1353-1356.
12. Berger S.P., Roos A., Mallat M.J., et al. Association between mannose-binding lectin levels and graft survival in kidney transplantation. Am J Transplant 2005, 5:1361-1366.
13. Berger S.P., Roos A., Mallat M.J., et al. Low pretransplantation mannose-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol 2007, 18:2416-2422.
14. Eurich D., Boas-Knoop S., Yahyazadeh A., et al. Role of mannose-binding lectin-2 polymorphism in the development of acute rejection after transplantation for hepatitis C virus-induced liver disease. Transpl Infect Dis 2012, 14:488-495.
15. Imai N., Nishi S., Alchi B., et al. Immunohistochemical evidence of activated lectin pathway in kidney allografts with peritubular capillary C4d deposition. Nephrol Dial Transplant 2006, 21:2589-2595.
16. Cervera C., Balderramo D., Suárez B., et al. Donor mannose-binding lectin gene polymorphisms influence the outcome of liver transplantation. Liver Transpl 2009, 15:1217-1224.
17. Fiane A.E., Ueland T., Simonsen S., et al. Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation. Eur Heart J 2005, 26:1660-1665.
18. Bay J.T., Sørensen S.S., Hansen J.M., et al. Low mannose-binding lectin serum levels are associated with reduced kidney graft survival. Kidney Int 2013, 83:264-271.
19. Eikmans M., de Canck I., van der Pol P., et al. The functional polymorphism Ala258Ser in the innate receptor gene ficolin-2 in the donor predicts improved renal transplant outcome. Transplantation 2012, 94:478-485.
20. Moreso Francesc, Ibernon Meritxell, Fernández-Real José M., et al. Low serum mannose-binding lectin are associated with inflammation, new-onset diabetes mellitus and subclinical rejection after renal transplantation. J Transl Med 2011, 9(Suppl. 2):30.
21. Damman J., Kok J.L., Snieder H., et al. Lectin complement pathway gene profile of the donor and recipient does not influence graft outcome after kidney transplantation. Mol Immunol 2012, 50(1-2):1-8.
22. Asgari E., Zhou W., Sacks S. Complement in organ transplantation. Curr Opin Organ Transplant 2010, 15:486-491.
23. Berger S.P., Daha M.R. Emerging role of the mannose-binding lectin dependent pathway of complement activation in clinical organ transplantation. Curr Opin Organ Transplant 2011, 16:28-33.
24. Krichen H., Sfar I., Bardi R., et al. CD86 +1057G>A polymorphism and susceptibility to acute kidney allograft rejection. Iran J Kidney Dis 2011, 5(3):187-193.
25. Tait B.D. Solid phase assays for HLA antibody detection in clinical transplantation. Curr Opin Immunol 2009, 21:573-577.
26. Poli F., Cardillo M., Scalamogna M. Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach. Hum Immunol 2009, 70:631-635.
27. Chang A.T., Platt J.L. The role of antibodies in transplantation. Transplant Rev (Orlando) 2009, 23:191-198.
28. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999, 55(2):713-723.
29. Hummelshoj T., Munthe-Fog L., Madsen H.O., et al. Functional SNPs in the human ficolin (FCN) genes reveal distinct geographical patterns. Mol Immunol 2008, 45:2508-2520.
30. Matsushita M., Endo Y., Fujita T. Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J Immunol 2000, 164:2281-2284.
31. Rantala A., Lajunen T., Juvonen R., et al. Mannose-binding lectin concentrations, MBL2 polymorphisms, and susceptibility to respiratory tract infections in young men. J Infect Dis 2008, 198:1247-1253.
32. Steffensen R., Thiel S., Varming K., et al. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 2000, 241:33-42.
33. Wasowska B.A. Mechanisms involved in antibody- and complement mediated allograft rejection. Immunol Res 2010, 47:25-44.
34. Garred P., Larsen F., Seyfarth J., et al. Mannose-binding lectin and its genetic variants. Genes Immun 2006, 7:85-94.
35. Sacks S.H., Chowdhury P., Zhou W. Role of the complement system in rejection. Curr Opin Immunol 2003, 15:487-492.
36. Slatinska J., Honsova E., Burgelova M., et al. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience. Ther Apher Dial 2009, 13:108-112.
37. Ahmed T., Senzel L. The role of therapeutic apheresis in the treatment of acute antibody- mediated kidney rejection. J Clin Apher 2012, 27:173-177.
38. Gubensek J., Buturovic-Ponikvar J., Kandus A., et al. Plasma exchange and intravenous immunoglobulin in the treatment of antibody-mediated rejection after kidney transplantation: a single-center historic cohort study. Transplant Proc 2013, 45:1524-1527.
39. Kim S.M., Lee C., Lee J.P., et al. Kidney transplantation in sensitized recipients; a single center experience. J Korean Med Sci 2009, 24:S143-S147. (Suppl).
40. Bohmih G., Regele H., Exner M., et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 2001, 12:2482-2489.
41. Bohmig G.A., Wahrmann M., Regele H., et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007, 7:117-121.
42. Faguer S., Kamar N., Guilbeaud-Frugier C., et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007, 83:1277-1280.
43. Hardinger K.L., Alford K., Murillo D. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience. Clin Transpl 2010, 429-436.